drugset
drugset / Trial / NCT01978613

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

NCT01978613 ↗

Phase 1 Completed 100 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of multiple doses of NNC0113-0987 in an oral formulation in healthy subjects.

Timeline

Start
2013-11
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0113-0987 Unknown 2.5 mg Oral
Subject NNC0113-0987 Unknown 5 mg Oral
Subject NNC0113-0987 Unknown 10 mg Oral
Subject NNC0113-0987 Unknown 20 mg Oral

Indications

diabetes mellitus